Actively Recruiting
An Open-label Multicenter Study Evaluating LBL-024 Combination Therapy Safety and Efficacy in Metastatic Colorectal Carcinoma Patients
Led by Nanjing Leads Biolabs Co.,Ltd · Updated on 2026-10-16
369
Participants Needed
10
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of LBL-024 combined with other drugs for treating metastatic colorectal carcinoma mCRC. This open-label, multi-center Phase IbII clinical trial aims to understand how well LBL-024 works with other therapies in patients with mCRC, including assessing safety and tolerability during early and later phases of the study. The study includes a Phase Ib safety introduction period and a Phase II randomized controlled extension period. Both phases involve two separate groups, Cohort 1 and Cohort 2, with different treatment combinations. Treatments include intravenous infusions and oral medications such as bevacizumab, oxaliplatin, capecitabine, fruquintinib, and LBL-024 in various combinations. Phase II enrollment and design depend on initial Phase Ib results, with randomization in Cohort 2 assigning participants to different treatment groups in a 21 ratio. Participants will undergo treatment and regular assessments including laboratory tests, imaging, and safety monitoring. Researchers will measure outcomes such as objective response rate, adverse events, disease control rate, duration of response, progression-free survival, overall survival, drug concentration levels, and immune response. The study includes a follow-up period after drug withdrawal lasting up to 90 days. The total duration of participation varies based on treatment and follow-up schedules.
CONDITIONS
Brief Title
A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma
Research Team
R
Ruihua Xu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here